Skip to main content

Phase 2 Metabolic & Obesity Deal Benchmarks

Median Upfront
$683M
Range: $375M - $979M
Total Deal Value
$3.2B
Range: $2.1B - $4.4B
Royalty Rate
14.6% - 26.7%
Tiered up to 30.7%
Dev Milestones
$460M
Range: $311M - $610M

Market Analysis

Phase 2 metabolic & obesity licensing deals carry a median total deal value of $3.2B, with upfront payments ranging from $375M to $979M. At this stage, deal structures are balanced between upfront and milestone payments, reflecting the proof-of-concept inflection. The recommended split allocates 21% to upfront and 79% to milestones.

The metabolic & obesity landscape at the phase 2 stage is characterized by extremely high competitive intensity driven by the GLP-1 revolution and massive obesity market opportunity. Development milestones average $460M, regulatory milestones contribute $562M, and commercial milestones reach $1.5B. Oral formulations, dual/triple incretins, and muscle-sparing approaches command unprecedented deal valuations.

Royalty rates for phase 2 metabolic & obesity deals range from 14.6% to 26.7% at the base tier, with high-tier escalation to 30.7%. Mid-stage royalties reflect the balance of de-risking achieved and remaining development investment.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the average upfront payment for phase 2 metabolic & obesity deals?
Phase 2 metabolic & obesity deals average $683M in upfront payments, ranging from $375M to $979M. The upfront allocation of 21% of total deal value reflects the clinical stage risk profile.
How are phase 2 metabolic & obesity deal milestones structured?
Milestones account for approximately 79% of total deal value. Development milestones ($460M) represent the largest component, followed by commercial milestones ($1.5B) and regulatory milestones ($562M).
What royalty rates are typical for phase 2 metabolic & obesity licensing?
Base royalty rates range from 14.6% to 26.7%, with tiered escalation to 18.6%-30.7% on peak sales. Rates are influenced by modality, competitive positioning, and territorial scope.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included